Full list, see https://orcid.org/0000-0002-1863-0305
TEN SELECTED PUBLICATIONS
1. Löf C, Sultana N, Goel N, Heron S, Wahlström G, House A, Holopainen M, Käkelä R, Schleutker J. ANO7 expression in the prostate modulates mitochondrial function and lipid metabolism. Cell Comm Signal, 23(1):71, 2025.
2. Metsälä O, Wahlström G, Goel N, Miihkinen M, Taimen P, Schleutker J. Spatial profiling of ANO7 in prostate tissue: links to AR-signaling-associated lipid metabolism and immune filtration. J Pathol, 265(4):518-531, 2025.
3. Kurki MI, …; Schleutker J, …; Daly MJ, Palotie A. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature, 613(7944):508-518, 2023.
4. Wahlström G, Heron S, Knuuttila M, Kaikkonen E, Tulonen N, Metsälä O, Löf C, Ettala O, Boström PJ, Taimen P, Poutanen M, Schleutker J. The variant rs77559646 associated with aggressive prostate cancer disrupts ANO7 mRNA splicing and protein expression. Hum Mol Genet, 31(12):2063-2077, 2022.
5. Sipeky C, Tammela TLJ, Auvinen A, Schleutker J. Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer Prostatic Dis, 24(4):1158-1166, 2021.
6. Huynh-Le MP, Fan CC, Karunamuni R, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir K, Schleutker J, …; Seibert TM. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nat Commun, 12(1):1236, 2021.
7. Sipeky C, Talala KM, Tammela TLJ, Taari K, Auvinen A, Schleutker J. Prostate cancer risk prediction using a polygenic risk score. Sci Rep, 10(1):17075, 2020.
8. Sipeky C, Gao P, Zhang Q, Wang L, Ettala O, Talala KM, Tammela TLJ, Auvinen A, PRACTICAL Consortium, Wiklund F, Wei G-H, Schleutker J. Synergistic interaction of HOXB13 and CIP2A predispose to aggressive prostate cancer. Clin Cancer Res, 24(24):6265-6276, 2018.
9. Gao P, …; Wang L, Schleutker J, Wei GH. Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. Cell, 174(3):576-589, 2018.
10. Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo J-P, Tammela T, Kellokumpu-Lehtinen P-L, PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei G-H, Schleutker J. ANO7 is associated with aggressive prostate cancer. Int J Cancer, 143(10):2479-2487, 2018.